Pediatric Dosage Formulation
A US-based global biopharmaceutical company known for its successful anti-infective products for adults was looking to reformulate the product into an age-appropriate dosage form for young children and pre-teen patients. The customer established a list of criteria for selecting a CDMO partner. Among its operational priorities, it identified:
- Maintaining as closely as possible the train of equipment used to manufacture its adult and adolescent formulations.
- Proven blending, compression, and coating capability, particularly of micro-tablets and oral granules.
- Ability to handle a variety of batch capacities: engineering, design of experiment protocol, clinical batch, registration, and validation; scaling to commercial production runs.
- International regulatory and significant commercial operational expertise.
- Expertise in cleaning requirements for low-dose formulations.
In this case study, we learn how Cambrex’s demonstrated flexibility, responsiveness, and cooperation led to multiple pediatric formulation projects from our client, and more importantly, a strategic partnership.